QUANTERIX CORP (QTRX)
US74766Q1013 - Common Stock
Overall QTRX gets a fundamental rating of 4 out of 10. We evaluated QTRX against 56 industry peers in the Life Sciences Tools & Services industry. While QTRX has a great health rating, there are worries on its profitability. While showing a medium growth rate, QTRX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
QTRX had negative earnings in the past year.
QTRX had a negative operating cash flow in the past year.
QTRX had negative earnings in each of the past 5 years.
In the past 5 years QTRX always reported negative operating cash flow.
1.2 Ratios
QTRX has a Return On Assets of -9.66%. This is comparable to the rest of the industry: QTRX outperforms 55.36% of its industry peers.
Looking at the Return On Equity, with a value of -11.79%, QTRX is in the better half of the industry, outperforming 60.71% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.66% | ||
| ROE | -11.79% | ||
| ROIC | N/A |
ROA(3y)-13.79%
ROA(5y)-15.4%
ROE(3y)-16.45%
ROE(5y)-19.27%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Gross Margin value of 57.42%, QTRX is doing good in the industry, outperforming 75.00% of the companies in the same industry.
In the last couple of years the Gross Margin of QTRX has grown nicely.
QTRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 57.42% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.15%
GM growth 5Y3.93%
2. Health
2.1 Basic Checks
QTRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for QTRX has been increased compared to 1 year ago.
Compared to 5 years ago, QTRX has more shares outstanding
QTRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 2.71 indicates that QTRX is not a great score, but indicates only limited risk for bankruptcy at the moment.
QTRX's Altman-Z score of 2.71 is in line compared to the rest of the industry. QTRX outperforms 58.93% of its industry peers.
There is no outstanding debt for QTRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.71 |
ROIC/WACCN/A
WACC11.66%
2.3 Liquidity
QTRX has a Current Ratio of 9.74. This indicates that QTRX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 9.74, QTRX belongs to the best of the industry, outperforming 89.29% of the companies in the same industry.
A Quick Ratio of 8.99 indicates that QTRX has no problem at all paying its short term obligations.
QTRX has a Quick ratio of 8.99. This is amongst the best in the industry. QTRX outperforms 89.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.74 | ||
| Quick Ratio | 8.99 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 67.05% over the past year.
Looking at the last year, QTRX shows a quite strong growth in Revenue. The Revenue has grown by 15.99% in the last year.
QTRX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 26.62% yearly.
EPS 1Y (TTM)67.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)15.99%
Revenue growth 3Y12.3%
Revenue growth 5Y26.62%
Sales Q2Q%13.93%
3.2 Future
QTRX is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -2.84% yearly.
Based on estimates for the next years, QTRX will show a quite strong growth in Revenue. The Revenue will grow by 15.76% on average per year.
EPS Next Y-15.28%
EPS Next 2Y-2.74%
EPS Next 3Y7.29%
EPS Next 5Y-2.84%
Revenue Next Year13.21%
Revenue Next 2Y14.35%
Revenue Next 3Y15.58%
Revenue Next 5Y15.76%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
QTRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year QTRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.74%
EPS Next 3Y7.29%
5. Dividend
5.1 Amount
QTRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
QUANTERIX CORP
NASDAQ:QTRX (12/18/2024, 4:30:01 PM)
After market: 10.33 0 (0%)10.33
-0.78 (-7.02%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap396.47M
Analysts
Price Target
Short Float %
Short Ratio
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.66% | ||
| ROE | -11.79% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 57.42% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.31
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 9.74 | ||
| Quick Ratio | 8.99 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)67.05%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-15.28%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)15.99%
Revenue growth 3Y12.3%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y